title: [Using metabolic cytoprotector Remaxol for urgently increased stability towards acute decompression syndrome].
abstract: The article deals with evaluation of efficiency of metabolic cytoprotector Remaxol as a medication for urgently increased stability towards acute decompression syndrome at severe degree, studied in experiments on 45 outbred male rabbits. Single intravenous injection of Remaxol relieves oxidant effects of inadequate decompression, lowers number of lethal outcomes due to acute decompression syndrome, increases survival time in the animals.
authors.forename: A V
authors.initials: AV
authors.lastname: Starovoĭt
authors.forename: V L
authors.initials: VL
authors.lastname: Pastushenkov
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Shitov
authors.forename: A A
authors.initials: AA
authors.lastname: Miasnikov
mesh_terms: D000208:Acute Disease; D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D003664:Decompression / Q000009:adverse effects*; D003665:Decompression Sickness / Q000378:metabolism / Q000517:prevention & control*; D004195:Disease Models, Animal; D007275:Injections, Intravenous; D050356:Lipid Metabolism / Q000187:drug effects*; D008297:Male; D011817:Rabbits; D013386:Succinates / Q000008:administration & dosage / Q000627:therapeutic use*; D013577:Syndrome; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; C555877:Remaxol; D013386:Succinates